AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer October 1, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines October 1, 2026
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015 October 1, 2026
$92.5M Series E Financing to Advance First-in-class Cyclin D1 Program CID-615 into Clinical Development Announced September 22, 2026
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 22, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Ph 2a Results September 22, 2026
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program September 16, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda in FAP-α Positive Solid Tumors September 16, 2026
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy September 16, 2026
First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology September 16, 2026
AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer September 9, 2026
Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Gen ADC Pipeline to Clinic September 9, 2026
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 with CD20xCD3 T-Cell-Engaging Bispecific Antibodies September 9, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy September 9, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development September 9, 2026
